Evidence map›Paper›PMID 29797174›Full record

ArticleMolecular biology reports2018

Cytotoxicity of doxrubicin loaded single-walled carbon nanotubes.

Ayhan Ünlü, Mehdi Meran, Bircan Dinc, Nilgün Karatepe, Muhammet Bektaş, F Seniha Güner

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ayhan ÜnlüDepartment of Biophysics, Faculty of Medicine, Trakya University, 22030, Edirne, Turkey. ayhan@trakya.edu.tr.ORCID http://orcid.org/0000-0001-6033-7148
Mehdi MeranDepartment of Chemical Engineering, Istanbul Technical University, 34469, Istanbul, Turkey.
Bircan DincDepartment of Basic Sciences, Faculty of Engineering and Natural Sciences, Altinbas University, 34218, Istanbul, Turkey.
Nilgün KaratepeInstitute of Energy, Istanbul Technical University, 34469, Istanbul, Turkey.
Muhammet BektaşDepartment of Biophysics, Istanbul Faculty of Medicine, Istanbul University, 34093, Istanbul, Turkey.
F Seniha GünerDepartment of Chemical Engineering, Istanbul Technical University, 34469, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carbon nanotube (CNTs) is a new alternative for efficient drug delivery and it has a great potential to change drug delivery system profile in pharmaceutical industry. One of the important advantage of CNTs is their needle-like, cylindrical shape. This shape provides a high surface area for multiple connections and adsorption onto for millions of therapeutic molecules. CNTs can be internalized by cells via endocytosis, passive diffusion and phagocytosis and release the drug with different effects like pH and temperature. The acidic nature of cancer cells and the susceptibility of CNTs to release the drug in the acidic environment have made it a promising area of research in cancer drug delivery. In this research, we investigated cell viability, cytotoxicity and drug delivery in breast cancer cell line by designing non-covalent single walled carbon nanotubes (SWNT)-doxorubicin (DOX) supramolecular complex that can be developed for cancer therapy. Applied high concentrations of DOX loaded SWNTs changed the actin structure of the cells and prevented the proliferation of the cells. It was showed that doxorubicin loaded SWNTs were more effective than free doxorubicin at relatively small concentrations. Once we applied same procedure for short and long (short: 1-1.3 µm; long: 2.5-4 µm) SWNTs and compared the results, more disrupted cell structure and reduction in cell proliferation were observed for long CNTs. DOX is bounded more to nanotubes in basic medium, less bound in acidic environment. Cancer cells were also examined for concentration at which they were effective by applying DOX and it was seen that 3.68 µM doxorubicin kills more than 55% of the cells.

Indexed as

Breast NeoplasmsCell Line, TumorCell SurvivalDoxorubicinDrug Delivery SystemsFemaleHumansMCF-7 CellsNanotubes, CarbonPolyethylene GlycolsDoxorubicinNanotubes, CarbonPolyethylene GlycolsCytotoxicityDoxorubicinMDA-MB-231NanotechnologySingle-walled carbon nanotubes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.